Agile Therapeutics Cash Flow - Quarterly (NASDAQ:AGRX)

Add to My Stocks
$3.03 $0.16 (5.02%) AGRX stock closing price Mar 16, 2018 (Closing)

The Agile Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Agile Therapeutics profits and Agile Therapeutics debt. Agile Therapeutics stock analysis shows negative net income cash flow of $-22.06M till 2017 Q3. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Agile Therapeutics saw a outflow of $-0.77M from investing activities till 2017 Q3.

View and download details of Agile Therapeutics cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow---------
Net Increase (Decrease) in Assets Liabilities-1.01M-1.28M-0.05M--0.11M-2.47M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net3.16M2.01M-4.13M3.19M1.88M-4.7M3.53M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.77M-0.45M-0.01M-0.03M-0.02M-0.02M--0.29M-0.28M
Acquisition Disposition of Subsidiaires---------
Increase (Decrease) in Investments---------
Other Cash Inflow (Outflow) from Investment Activities---------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares18.61M--37.86M37.85M37.84M37.84M19.92M19.86M
Issuance (Repayment) of Debt Securities-4.03M-2.49M-0.99M------
Increase (Decrease) in Bank & Other Borrowings---------
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities----0.17M-0.17M---0.42M-0.42M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year34.39M40.18M2.11M20.01M9.56M----
Cash & Equivalents at Year End43.8M33.93M41.74M48.75M51.67M59.22M65.49M34.39M39.4M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Agile Therapeutics stock price history and Agile Therapeutics stock comparison chart inevitably reflect its cash flow situation.

  • Agile Therapeutics had a Net Change in Cash and Cash Equivalents of $-4.94M in the latest quarter 2017 Q3. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Agile Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-18.75M for AGRX.
  • Cash Flow from investment activities: Agile Therapeutics used $-0.77M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $14.57M for Agile Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Agile Therapeutics Cash Flow

Quarterly Cash Flow Statements For Agile Therapeutics Inc Peers

Juniper Pharma cash flow, Merck cash flow, Pfizer cash flow, Teligent cash flow, Zynerba Pharma cash flow